Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

Partner | Cancer Centers | <b>Sarah Cannon</b>

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

During the 2021 ESMO Congress, preliminary findings from the phase 1 TROPION-PanTumor01 trial (NCT03401385) were presented. The results demonstrated a 35% overall response rate and a median duration of response of 9.5 months with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan in patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) and actionable genomic alterations.

The emergence of trials evaluating datopotamab deruxtecan have underscored the potential utility of TROP2-directed therapies, Johnson says. TROP2 appears to be pervasive in NSCLC, as well as small cell lung cancer, breast cancer, head and neck cancer, and gastric/gastroesophageal junction cancer.

Although it is early, datopotamab deruxtecan could show similar tumor-agnostic activity as that with pembrolizumab (Keytruda), which is FDA approved for use in adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (≥10 mut/Mb) solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options, Johnson concludes.

This activity is funded in part by Daiichi Sankyo. Content independently produced by OncLive.